Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | ‫| اﻟﻌرﺑﯾﺔ‬

PATENTSCOPE
Search International and National Patent Collections

Search Browse Translate Options News Login Help

Home IP Services PATENTSCOPE

Results 1-10 of 36,503 for Criteria:bio-prospecting Office(s):all Language:EN Stemming: true

prev 1 2 3 4 5 6 7 8 9 10 next Page: 1 / 3651 Go >

Refine bio-prospecting Search

Search

Instant Help

Analysis

Sort by: Pub Date Desc View All List Length 10 Machine translation
Title Ctr PubDate
Int.Class Appl.No Applicant Inventor
1. WO/2018/054484 BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN 6 OR CLAUDIN18.2 AND CD3 FOR TREATMENT OF WO 29.03.2018
CLAUDIN EXPRESSING CANCER DISEASES
C07K 16/28 PCT/EP2016/072688 BIONTECH AG SAHIN, Ugur
The present disclosure provides binding agents comprising at least three binding domains, wherein a first binding domain binds to a T cell-specific antigen and a second
binding domain and a third binding domain bind to a claudin, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

2. WO/2018/054720 OPTIMIZED METHOD FOR !ARGE SCALE PRODUCTION OF PARVOVIRUS H-1 IN AN ESSENTIALLY SERUM-FREE WO 29.03.2018
MEDIUM
C12N 7/00 PCT/EP2017/072872 DEUTSCHES KREBSFORSCHUNGSZENTRUM LEUCHS, Barbara
Described is an optimized process for parvovirus production including an essentially serum-free medium which is suitable to increase parvovirus production compared to
a standard medium, preferably for H-1 PV production.

3. WO/2018/054973 BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN6 OR CLAUDIN18.2 AND CD3 FOR TREATMENT OF WO 29.03.2018
CLAUDIN EXPRESSING CANCER DISEASES
C07K 16/28 PCT/EP2017/073773 BIONTECH AG SAHIN, Ugur
The present disclosure provides binding agents comprising at least three binding domains, wherein a first binding domain binds to a T cell-specific antigen and a second
binding domain and a third binding domain bind to a claudin, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

4. WO/2018/055005 FLEXIBLE ELECTRONIC COMPONENTS AND METHODS FOR THEIR PRODUCTION WO 29.03.2018
D06M 11/58 PCT/EP2017/073827 CAMBRIDGE ENTERPRISE LIMITED TORRISI, Felice
A flexible electronic component in this disclosure comprises a flexible fabric substrate and a smoothing layer formed on the flexible fabric substrate. A layer of
nanoplatelets derived from a layered materialis deposited on the smoothing layer by inkjet printing. The layer of nanoplatelets may form a first layer of a first nanoplatelet
material and there may be provided at least a second layer, of a different nanoplatelet material, formed at least in part on the first layer. First and second electrodes are
provided in contact respectively with the first and second layers.

5. WO/2018/055209 METHOD FOR THE DIAGNOSIS OF ACUTE PANCREATITIS (AP) BY DETECTION OF GLYCOPROTEIN 2 ISOFORM WO 29.03.2018
ALPHA (GP2A)
G01N 33/68 PCT/EP2017/074405 GA GENERIC ASSAYS GMBH ROGGENBUCK,
Dirk
The invention relates to an in vitro method for the diagnosis of acute pancreatitis (AP) in a subject by detection of Glycoprotein 2 isoform alpha (GP2a) protein. In
particular the invention pro- vides an in vitro method for the diagnosis of acute pancreatitis (AP) in a subject by detection of Glycoprotein 2 isoform alpha (GP2a) protein,
comprising providing a sample of a human subject exhibiting symptoms of having pancreatic disease, wherein said sample is obtained from the subject within 72 hours
of the appearance of said symptoms, providing an affinity reagent directed against GP2a, contacting said sample with said affinity reagent thereby capturing GP2a from
said sample, and determining the concentration of GP2a from said sample, wherein determining a concentration of GP2a in said sample that is greater than the average
concentration of GP2a in control samples, such as in a group of healthy individuals, indicates the presence of AP and the absence of one or more of chronic
pancreatitis, pancreatic cancer, gastrointestinal cancer, liver cancer, neuroendocrine tumor, sarcoma, peptic ulcer or peritonitis. The invention further provides a kit and a
system developed for carrying out the claimed method and determining the concentration of GP2a and performing an automated analysis of one or more samples.

6. WO/2018/055404 COMPOSITE MATERIAL WO 29.03.2018

C01B 32/182 PCT/GB2017/052851 IMPERIAL INNOVATIONS LIMITED KARAN, Santanu
Composite materials are described, as well as their processes of preparation, and their specific uses. The composite materials comprise a 2-dimensional carbon thin
film and at least one further material, where the 2-dimensional carbon thin films are fabricated by preparing an organic polymeric thin film precursor, which is then
subjected to a carbonisation process to remove at least some of the non-carbon atoms. Using the disclosed process, composite materials having improved dimensional
characteristics can be reliably prepared, which presents clear advantages in applications which have until now been restricted to the use of 2- dimensional carbon thin
films having less useful dimensions.

7. WO/2018/055574 TREATING REFRACTORY MIGRAINE WO 29.03.2018

C07K 16/18 PCT/IB2017/055777 TEVA PHARMACEUTICALS INTERNATIONAL GMBH BIGAL, Marcelo
Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject
having refractory migraine comprising administering to the subject a 5 monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed
methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

8. WO/2018/057051 AFFINITY-OLIGONUCLEOTIDE CONJUGATES AND USES THEREOF WO 29.03.2018